small molecule

OMNICEF

CEFDINIR

Loss of exclusivity—loss of exclusivity

CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	OMNICEF
Active ingredient	CEFDINIR
Strength	300MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	December 1997
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.